DOCSLIB.ORG

A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al US009078919B2 a2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet al. (45) Date of Patent: *Jul. 14, 2015 (54) MICRO-RNAS OF THE MIR-15 FAMILY 2005/0182011 Al 8/2005 Olson etal. MODULATE CARDIOMYOCYTE SURVIVAL 2006/0058266 Al 3/2006 Manoharan etal. AND CARDIAC REPAIR 2006/0105360 Al 5/2006 Croce etal. 2006/0165659 Al 7/2006 Croceet al. 2006/0185027 Al 8/2006 Bartelet al. (71) Applicant: The Board of Regents, The University 2006/0189557 Al 8/2006 Slack et al. of Texas System, Austin, TX (US) 2006/0247193 Al 11/2006 Taira et al. 2006/0252722 Al 11/2006 Lollo et al. (72) Inventors: Eric N. Olson, Dallas, TX (US); Eva 2007/0026403 Al 2/2007 Hatzigeorgiouetal. 2007/0054287 Al 3/2007 Bloch van Rooij, Utrecht (NL) 2007/0213292 Al 9/2007 Stoffel et al. 2007/0259827 Al 11/2007 Aronin et al. (73) Assignee: The Board of Regents, the University 2007/0287179 Al 12/2007 Tuschletal. of Texas System, Austin, TX (US) 2007/0292878 Al 12/2007 Raymond. 2008/0050744 Al 2/2008 Brownetal. (*) Notice: Subject to any disclaimer, the term of this 2008/0176766 Al 7/2008 Brownetal. 2008/0220423 Al 9/2008 Molleret al. patent is extended or adjusted under 35 2009/0053718 Al 2/2009 Naguibnevaetal. U.S.C. 154(b) by 0 days. 2009/0092980 Al 4/2009 Arenzet al. 2009/0131356 Al 5/2009 Baderet al. This patent is subject to a terminal dis- 2009/0176723 Al 7/2009 Brownetal. claimer. 2009/0214477 Al 8/2009 Betzet al. 2009/0221685 Al 9/2009 Esauetal. (21) Appl. No.: 13/970,379 2009/0226528 Al 9/2009 Czechet al. 2009/0281167 Al 11/2009 Shenetal. (22) Filed: Aug. 19, 2013 2009/0286969 Al 11/2009 Esauet al. 2009/0286973 Al 11/2009 Manoharan etal. 2009/0291906 Al 11/2009 Esauet al. (65) Prior Publication Data 2009/0291907 Al 11/2009 Esauet al. US 2014/0051745 Al Feb. 20, 2014 2009/0293148 Al 11/2009 Renetal. 2009/0298174 Al 12/2009 Esauet al. 2009/0306181 Al 12/2009 Ikedaet al. 2009/0326049 Al 12/2009 Aristarkhovet al. Related U.S. Application Data 2010/0029003 Al 2/2010 Bartel et al. 2010/0069471 Al 3/2010 Manoharan etal. (63) Continuation of application No. 12/742,233, filed as 2010/0087512 Al 4/2010 Tuschletal. application No. PCT/US2008/083020 on Nov. 10, 2010/0087513 Al 4/2010 Tuschletal. 2008, now Pat. No. 8,513,209. (Continued) (60) Provisional application No. 60/986,798,filed on Nov. 9, 2007. FOREIGN PATENT DOCUMENTS (51) Int. Cl. EP 1627925 Al 2/2006 AG6IK 48/00 (2006.01) EP 1676914 Al 7/2006 AGIK 45/06 (2006.01) (Continued) AOIK 67/027 (2006.01) CIIN 15/113 (2010.01) OTHER PUBLICATIONS AGIK 31/7105 (2006.01) (52) U.S.C Young, “International Search Report,” 4 pages, from International CPC veeceseseeee A61K 45/06 (2013.01); AOLK 67/0275 Patent Application No. PCT/US08/83020, USPTO, Alexandria, Vir- (2013.01); A6LK 31/7105 (2013.01); C12N ginia, US (mailed May 13, 2009). 15/113 (2013.01); AOLK 2207/05 (2013.01); (Continued) AOLK 2217/058 (2013.01); AOLK 2227/105 (2013.01); AOLK 2267/0375 (2013.01); C12N 2310/113 (2013.01); CI2N 2310/14 (2013.01); Primary Examiner — Kimberly Chong C12N 2330/10 (2013.01); C12N 2830/008 (2013.01) (74) Attorney, Agent, or Firm — Cooley LLP (58) Field of Classification Search None (57) ABSTRACT See application file for complete search history. A family of microRNAs, called the miR-15 family, which (56) References Cited includes miR-195, are shown to be up-regulated during U.S. PATENT DOCUMENTS pathological cardiac remodeling and repress the expression of mRNAsrequired for cell proliferation and survival, with 7,232,806 B2 6/2007 Tuschletal. consequent loss of cardiomyocytes. Strategies to block 7,482,117 B2 1/2009 Cargill et al. expression ofthe miR-15 family in the heart as a treatment for 7,582,744 B2 9/2009 Manoharan et al. diverse cardiac disease are provided. 7,759,319 B2 7/2010 Lollo et al. 2005/0026169 Al 2/2005 Cargill et al. 2005/0059005 Al 3/2005 Tuschlet al. 2005/0075492 Al 4/2005 Chenetal. 18 Claims, 9 Drawing Sheets US 9,078,919 B2 Page 2 (56) References Cited WO WO2008/061537 A2 5/2008 WO _-WO 2008/073920 A2 —-6/2008 — U.S. PATENT DOCUMENTS WO WO 2008/073921 A2 6/2008 WO WO 2008/073922 A2 6/2008 2010/0093837 Al 4/2010 Tuschlet al. WO WO 2008/073923 A2 6/2008 —_ 2010/0099748 Al 4/2010 Tuschlet al. WO WO 2008/074328 A2 6/2008 2010/0113284 Al 5/2010 Aristarkhovet al. WO WO 2008/085797 A2 7/2008 2010/0113561 Al 5/2010 Tuschlet al. WO WO 2008/112226 A2 —_-9/2008 WO WO 2008/116267 Al 10/2008 — WO WO 2008/147430 A2 12/2008 — FOREIGN PATENT DOCUMENTS WO WO 2008/147839 Al 12/2008 — WO WO 2009/012263 A2 1/2009 EP 1777301 A2 4/2007 WO WO 2009/043353 A2 4/2009 EP 1959012 A2 8/2008 WO WO 2009/044895 Al 4/2009 EP 2105145 Al 9/2009 WO WO 2009/058818 A2 5/2009 EP 2113567 Al 11/2009 WO WO 2009/062169 A2 5/2009 JP 2006-506469 2/2006 WO WO 2009/121031 Al 10/2009 JP 2006-5 19008 8/2006 WO WO 2009/149182 Al 12/2009 JP 2006-292367 10/2006 WO WO 2010/036939 A2 4/2010 WO WO 03/029459 A2 4/2003 WO WO 2010/048585 A2 4/2010 WO WO 03/093441 A2 11/2003 WO WO 2004/043387 A2 5/2004 OTHER PUBLICATIONS WO WO 2004/076622 A2 9/2004 WO WO 2005/013901 A2 2/2005 Lagos-Quintanaet al., “New microRNAsfrom mouse and. human,” Wo WO 2005/017145 Al 2/2005 WO WO 2005/040419 Al 5/2005 RNA,vol. 9:175-179, 2003. — Wo WO 2005/056797 Al 6/2005 Lagos-Quintanaet al., “Identification of tissue-specific microRNAs WO WO 2005/078096 A2 8/2005 from mouse,” Current Biology, vol. 12:735-739, 2002. WO WO2005/078139 A2 8/2005 Sempere et al., “Expression profiling of mammalian microRNAs —- WoO WO 2005/097205 A2 10/2005 uncoversa subset ofbrain-expressed microRNAswith possible roles — WO WO 2005/098029 A2 10/2005 in murine and human neuronal differentiation”’ Genome Biology, — WO WO 2005/118806 A2 12/2005 = vol. 5:R13, 2004. WO WO 2006/020768 A2 2/2006 Wo WO 2006/048553 Al 5/2006 Van Rooij et al. “A signature pattern of stress-responsive Wo WO 2006/063356 Al 6/2006 microRNAsthat can evoke cardiac hypertrophy and heart failure,” Wo WO 2006/071884 A2 7/2006 Proc. Natl. Acad. Sci. USA, vol. 103: 18255-18260, 2006. WO WO 2006/108473 Al 10/2006 Landgrafet al., “A mammalian microRNAexpression atlas based on — WO WO 2006/111512 Al 10/2006 small RNAlibrary sequencing.” Cell, vol. 129: 1401-1414, 2007. WO WO 2006/133022 A2 12/2006 Landgrafet al., “A mammalian microRNAexpressionatlas based on — wo wo soooOooce& “ pos sma RNA library sequencing,” Cell, Supplementary Table S12, we we Rees ‘ seen Van Rooij et al., “Control of stress-dependent cardiac growth and WO WO 2007/044362 A2 4/2007 gene expression by a microRNA,”Science, vol. 316: 575-579, 2007. Wo WO 2007/053184 A2 5/2007 Van Roojj et al., “MicroRNA function during cardiac hypertrophy,” WO WO2007/056826 Al 5/2007 Abstract and Poster from 3rd Annual Symposium of the American Wo WO 2007/087451 A2 8/2007 Heart Association Council on Basic Cardiovascular Sciences: Trans- WO WO 2007/089607 A2 8/2007 lation of Basic Insights Into Clinical Practice: Jul. 31-Aug. 3, 2006 WO WO2007/090073 A2 8/2007 Keystone Conference Center Keystone, CO. — WO WO2007/092181 A2 8/2007 Ping et al., “The Study and Use of Antisense Oligonucleotide Tech- WO WO 2007/092182 A2 8/2007 nique in Cardiovascular Diseases,” Chinese Journal of Clinical Phar- WO WO 2007/095387 A2 8/2007 macology and Therapeutics, vol. 11: 241-245, 2006. WO WO 2007/103808 A2 9/2007 English Translation of Examination Report for Chinese Application WO WO 2007/112754 A2 10/2007 — WO WO 2007/147067 A2 12/2007 No. 200880 124495.1 issued Nov. 14, 2011. - wo WO 2007/147409 A2 12/2007 Seranski, Supplementary European Search Report and Opinion for wo WO 2008/024499 A? 2/2008 European Application No. 08847645.2, 9 pages, European Patent wo WO 2008/036776 A2 3/2008 Office, Munich, mailed Jan. 27, 2012. WO WO 2008/042231 A2 4/2008 Young, Written Opinion of the International Search Authority for WO WO 2008/043521 A2 4/2008 PCT/US2008/083020, 7 pages, mailed May 13, 2009. B2 L eanci ULTOUWORS Lue 9,078,919 avi Aq peyninBey | US mFei3g nie,umoy nhesdr i Beh Pole) 9 of 1 Sheet 2015 14, Jul. Rey CHEOBIOYL Patent U.S. B2 9,078,919 US 9 GR ya OSL wwe = of 2 BYALCUOUE POPU Sheet 2015 14, | YEG LAA YEOLAS Jul. LE wah WG2L wel PE aoe wie LE RU SyMMCopageiianir: Patent U.S. U.S. Patent Jul. 14, 2015 Sheet 3 of 9 US 9,078,919 B2 A microRNAsignature of the hypertrophic heart Normal | Failing Fold miR-23 _ miR-24 1.5 miR-125b 1.3 miR-195 3.0 miR-199a 2.1 miR-214 1.6 Figure 2 U.S. Patent Jul. 14, 2015 Sheet 4 of 9 US 9,078,919 B2 € &&. &.8 we OS neo 8‘ x* SyYBOMA FZ SHAM O 3 PiQure B2 py aunbi4 Awa ‘Soc ae mean 2 smwom@ aL pus E | [ ann ot ceo [ ue o 9,078,919 | 1 L, US +3 ‘et ret ca PT 9 dNd S6l VNU q of 5 Sheet OL Be n 2 se) ame 2015 FRB 14, RR Jul.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Asymmetric Organocatalyzed Synthesis of Coumarin Derivatives
    Asymmetric organocatalyzed synthesis of coumarin derivatives Natália M. Moreira‡, Lorena S. R. Martelli‡ and Arlene G. Corrêa* Review Open Access Address: Beilstein J. Org. Chem. 2021, 17, 1952–1980. Centre of Excellence for Research in Sustainable Chemistry, https://doi.org/10.3762/bjoc.17.128 Department of Chemistry, Federal University of São Carlos, 13565-905 São Carlos, SP – Brazil Received: 08 March 2021 Accepted: 21 July 2021 Email: Published: 03 August 2021 Arlene G. Corrêa* - [email protected] This article is part of the thematic issue "New advances in asymmetric * Corresponding author ‡ Equal contributors organocatalysis". Keywords: Guest Editor: R. Šebesta asymmetric synthesis; green chemistry; 2H-chromen-2-one; organocatalysis © 2021 Moreira et al.; licensee Beilstein-Institut. License and terms: see end of document. Abstract Coumarin derivatives are essential scaffolds in medicinal and synthetic chemistry. Compounds of this class have shown important activities, such as anticancer and antiparasitic, besides the commercially available drugs. These properties led to the development of efficient and greener synthetic methods to achieve the 2H-chromen-2-one core. In this context, the advances in asymmetric organocatalyzed synthesis of coumarin derivatives are discussed in this review, according to the mode of activation of the catalyst. Introduction Coumarins are important naturally occurring plant constituents and display a wide range of pharmacological and biological ac- tivities, such as anticancer [1], antibacterial [2], and
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Reactivity and Alkylating Potential of Some O-Heterocycles
    Dpto. de Qu´ımica f´ısica Facultad de Ciencias Qu´ımicas PhD Thesis Chemical processes that can damage cellular DNA: Reactivity and alkylating potential of some O-heterocycles Supervisors: Author: Prf. Dr. Julio Casado Rafael Gomez´ Bombarelli Prf. Dr. Emilio Calle November 8, 2011 A Marta, Jose,´ Lali y Pepe en ningun´ orden en particular Departamento de Qu´ımica f´ısica Facultad de Ciencias Qu´ımicas The work reported here has been carried out in the Departamento de Qu´ımica f´ısica of the Universidad de Salamanca, under the advice of Prof. Dr. Julio Casado Linarejos and Prof. Dr. Emilio Calle Mart´ın. Rafael Gomez´ Bombarelli Emilio Calle Mart´ın Julio Casado Linarejos It’s been emotional. Big Chris Acknowledgements The author thanks the Spanish Ministerio de Educacion´ for a PhD fellowship (AP2006-01976) and financed research stays at the workgroups of Prof. Dr. Jose´ Rueff (Universidade Nova de Lisboa) and Prof. Dr. Franc¸ois Maurel (ITODYS, Paris-VII), who are also thanked for their hos- pitality. Financial support of the research reported in this work by the Ministerio de Ciencia e Innovacion´ (projects CTQ2010-18999, CTQ2007-63263, CTQ2004-05048), and the Junta de Castilla y Leon´ and European Regional Development Fund (project SA040A08) is also ac- knowledged. E. Bombarelli and J. Arenas are also thanked for their generous donation of CPU-time and resources. i Contents List of Figuresv List of Tables vii List of Schemes ix Abbreviations xi Preface xiii 1 Alkylating agents and the NBP Test: a review 1 1.1 Development of the method....................5 1.1.1 Early examples.......................5 1.1.2 The Epstein test.......................6 1.1.3 Biological samples......................7 1.1.4 Chromatography......................7 1.2 NBP as a DNA-model.......................8 1.2.1 Nucleophilicity of DNA....................8 1.2.2 Site selectivity......................
    [Show full text]
  • Piperidine Derivatives Piperidinderivate Derives De Piperidine
    (19) TZZ_¥Z_T (11) EP 1 669 350 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/58 (2006.01) C07D 401/06 (2006.01) 29.02.2012 Bulletin 2012/09 C07D 401/14 (2006.01) C07D 401/02 (2006.01) C07D 401/12 (2006.01) C07D 409/12 (2006.01) (2006.01) (2006.01) (21) Application number: 04787951.5 A61K 31/4545 A61K 31/496 A61K 31/454 (2006.01) A61K 31/4523 (2006.01) A61K 31/4535 (2006.01) A61K 31/506 (2006.01) (22) Date of filing: 21.09.2004 A61P 43/00 (2006.01) A61P 3/04 (2006.01) A61P 3/10 (2006.01) A61P 5/00 (2006.01) A61P 3/06 (2006.01) A61P 19/06 (2006.01) A61P 9/10 (2006.01) A61P 9/04 (2006.01) A61P 9/12 (2006.01) (86) International application number: PCT/JP2004/013768 (87) International publication number: WO 2005/028438 (31.03.2005 Gazette 2005/13) (54) PIPERIDINE DERIVATIVES PIPERIDINDERIVATE DERIVES DE PIPERIDINE (84) Designated Contracting States: • TOKITA, Shigeru, AT BE BG CH CY CZ DE DK EE ES FI FR GB GR c/o Tsukuba Research Institute HU IE IT LI LU MC NL PL PT RO SE SI SK TR Tsukuba-shi, Designated Extension States: Ibaraki 3002611 (JP) LT LV • KANATANI, Akio, c/o Tsukuba Research Institute (30) Priority: 22.09.2003 JP 2003330758 Tsukuba-shi, Ibaraki 3002611 (JP) (43) Date of publication of application: 14.06.2006 Bulletin 2006/24 (74) Representative: Rollins, Anthony John et al Merck Sharp & Dohme Limited (73) Proprietor: MSD K.K.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Subarachnoid Haemorrhage
    Instrument No.48 of 1999 Revocation and Determination of Statement of Principles concerning SUBARACHNOID HAEMORRHAGE ICD-9-CM CODE: 430 Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.384 of 1995; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about subarachnoid haemorrhage and death from subarachnoid haemorrhage. (b) For the purposes of this Statement of Principles, “subarachnoid haemorrhage” means bleeding into the subarachnoid space, including rupture into the subarachnoid space of an intracranial saccular aneurysm or arteriovenous malformation, attracting ICD- 9-CM code 430. This definition includes subarachnoid haemorrahage due to bleeding disorder from anticoagulant therapy or thrombolytic therapy and excludes haemorrhage due to other bleeding disorders, haemorrhage due to cerebral tumour, or haemorrhage due to trauma to the brain or to the skull. Page 1 of 6 of Instrument No.48 of 1999. Basis for determining the factors 3. The Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that subarachnoid haemorrhage and death from subarachnoid haemorrhage can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces. Factors that must be related to service 4. Subject to clause 6, at least one of the factors set out
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Heparin EDTA Patent Application Publication Feb
    US 20110027771 A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0027771 A1 Deng (43) Pub. Date: Feb. 3, 2011 (54) METHODS AND COMPOSITIONS FORCELL Publication Classification STABILIZATION (51) Int. Cl. (75)75) InventorInventor: tDavid Deng,eng, Mountain rView, V1ew,ar. CA C09KCI2N 5/073IS/00 (2006.01)(2010.01) C7H 2L/04 (2006.01) Correspondence Address: CI2O 1/02 (2006.01) WILSON, SONSINI, GOODRICH & ROSATI GOIN 33/48 (2006.01) 650 PAGE MILL ROAD CI2O I/68 (2006.01) PALO ALTO, CA 94304-1050 (US) CI2M I/24 (2006.01) rsr rr (52) U.S. Cl. ............ 435/2; 435/374; 252/397:536/23.1; (73) Assignee: Arts Health, Inc., San Carlos, 435/29: 436/63; 436/94; 435/6: 435/307.1 (21) Appl. No.: 12/847,876 (57) ABSTRACT Fragile cells have value for use in diagnosing many types of (22) Filed: Jul. 30, 2010 conditions. There is a need for compositions that stabilize fragile cells. The stabilization compositions of the provided Related U.S. Application Data inventionallow for the stabilization, enrichment, and analysis (60) Provisional application No. 61/230,638, filed on Jul. of fragile cells, including fetal cells, circulating tumor cells, 31, 2009. and stem cells. 14 w Heparin EDTA Patent Application Publication Feb. 3, 2011 Sheet 1 of 17 US 2011/0027771 A1 FIG. 1 Heparin EDTA Patent Application Publication Feb. 3, 2011 Sheet 2 of 17 US 2011/0027771 A1 FIG. 2 Cell Equivalent/10 ml blood P=0.282 (n=11) 1 hour 6 hours No Composition C Composition C Patent Application Publication Feb.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al
    USO08080578B2 (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett et al. (45) Date of Patent: *Dec. 20, 2011 (54) METHODS FOR TREATMENT WITH 5,998.458. A 12/1999 Bristow ........................ 514,392 BUCNDOLOL BASED ON GENETIC 6,004,744. A 12/1999 Goelet et al. ...... 435/5 6,013,431 A 1/2000 Söderlund et al. 435/5 TARGETING 6,156,503 A 12/2000 Drazen et al. ..... ... 435/6 6,221,851 B1 4/2001 Feldman ... 51446 (75) Inventors: Stephen B. Liggett, Clarksville, MD 6,316,188 B1 1 1/2001 Yan et al. .......................... 435/6 6,365,618 B1 4/2002 Swartz ... 514,411 (US); Michael Bristow, Englewood, CO 6,498,009 B1 12/2002 Liggett ............................. 435/6 (US) 6,566,101 B1 5/2003 Shuber et al. 435,912 6,586,183 B2 7/2003 Drysdale et al. .................. 435/6 (73) Assignee: The Regents of the University of 6,784, 177 B2 8/2004 Cohn et al. 514,248 Colorado, a body corporate, Denver, 6,797.472 B1 9/2004 Liggett ......... ... 435/6 6,821,724 B1 1 1/2004 Mittman et al. ... 435/6 CO (US) 6,861.217 B1 3/2005 Liggett ......... ... 435/6 7,041,810 B2 5/2006 Small et al. ... ... 435/6 (*) Notice: Subject to any disclaimer, the term of this 7, 195,873 B2 3/2007 Fligheddu et al. ... 435/6 patent is extended or adjusted under 35 7,211,386 B2 5/2007 Small et al. ....... ... 435/6 7,229,756 B1 6/2007 Small et al.
    [Show full text]